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Abstract
Introduction: Hemoptysis constitutes a common and urgent medical problem. Swift and effective management is
of crucial importance, especially in severe, life-threatening cases. In cases of idiopathic hemoptysis, in which no
underlying pulmonary pathology can be identified, treatment is challenging. We report our experience with
bronchial artery embolization in the treatment of massive idiopathic hemoptysis.
Cases presentation: We report three consecutive cases of acute severe idiopathic hemoptysis. Our patients (two
men aged 51 and 56 years and one woman aged 46 years), were of Caucasian ethnicity. We discuss the results
and management of the patients, and review the literature. All three patients were treated safely and successfully
with transcatheter embolization of the bronchial arteries using tris-acryl gelatin microspheres. Hemoptysis was
controlled. All cases were followed up for 12 months, and there was no recurrence of bleeding.
Conclusion: Bronchial artery embolization is an effective tool for the evaluation and treatment of massive
idiopathic hemoptysis.
Introduction
Hemoptysis is the expectoration of blood originating
from the lower respiratory tract. Most cases are minor
and treatable or self-limiting. The bleeding may occur
from the large or small pulmonary vessels. Bleeding
from the small vessels is known as diffuse alveolar
hemorrhage [1]. Hemoptysis from the large vessels has
multiple known etiologies, including lung neoplasms,
bronchiectasis, tuberculosis, pulmonary vasculitis, cardi-
ovascular diseases and aspergilloma. However, in a num-
ber of cases, a cause cannot be determined, and these
are categorized as idiopathic hemoptysis [2,3]. The defi-
nition of severe or massive hemoptysis varies, but is
usually defined as the expectoration of 300-600 ml of
blood in 24 hours, or bronchial blood loss that causes
hemodynamic or respiratory compromises. Hemoptysis,
when severe and untreated, has a mortality rate of more
than 50% [2-4]. Bronchoscopy combined with imaging
technology usually identifies the bleeding site in the
lungs, but in 15-20% of cases the cause of hemoptysis
cannot be fully determined [3,5]. When diagnostic tools
fail to identify the source of bleeding, severe hemoptysis
becomes an emergency because failure to contain it can
lead to death. Bronchial arteriography and bronchial
artery embolization (BAE) may provide an effective
means of rapid diagnosis and treatment of such medical
emergencies [2,3,5].
BAE is a well-established, non-surgical procedure in
the treatment of hemoptysis [3,5,6]. BAE has emerged
in recent years as a treatment for severe, life-threatening
hemoptysis, and has revolutionized the management of
the disease, providing a reliable, minimally invasive tool
with excellent diagnostic and therapeutic outcomes
[3,5]. It was first described in 1973 by Remy et al. [7].
Subsequently, the procedure was rapidly and widely
used as a treatment for severe hemoptysis, proving to be
safe and efficient, and thus reducing the need for emer-
gency thoracic surgery [8,9]. Embolization may be life-
saving; it may postpone or replace surgery, and in some
situations it is the treatment of choice.
Case presentation
Three consecutive patients (two men aged 51 and 56 years
and one woman aged 46 years), of Caucasian ethnicity,
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were treated with BAE in a tertiary academic reference
center for spontaneous acute massive hemoptysis. All
three were active smokers with a mean smoking habit of
50 ± 29 pack years. None had any history of chronic ill-
ness, pulmonary or otherwise. All three patients exhibited
severe hemoptysis, ranging from 300 to 700 mL/day, with
multiple episodes. They also had hypoxemia, anemia and
low blood pressure. They were admitted to the intensive
care unit for close monitoring and treatment.
Two of our patients received blood transfusions
because of a rapid fall in hemoglobin levels (e.g. patient
1 had a hemoglobin level of 15.2% on admission, which
had dropped to 8.7% two days later) and fear of severe
hemodynamic instability,. All three of our patients were
managed according to a standard hemoptysis protocol.
They underwent emergency bronchoscopy and com-
puted tomography (CT) of the thorax to identify the site
of bleeding. The bronchoscopy did not allow identifica-
tion of the bleeding lobe or any other significant
abnormality in any of our patients. Blood trails and clots
were seen in both the left and right bronchial systems,
but provided no conclusive evidence as to the origin of
bleeding. A tuberculin skin test and Ziehl-Neelsen
examination of sputum indicated that our patients were
negative for tuberculosis, and bronchial lavage cytology
was negative for malignancy. The CT scan of one
patient showed some degree of centrilobular emphy-
sema. In all three cases, ‘ground glass’ attenuation con-
sistent with hemorrhagic debris was found in both
lungs, with predominance of one side or the other in
each case. At that point, surgical management was not
deemed feasible because the exact bleeding lobe could
not be identified.
The next step was bronchial angiography followed by
embolization. Under local anesthesia, the common
femoral artery was percutaneously punctured, and a 5F
introduction sheath was inserted. A flush catheter was
advanced into the upper part of the descending thoracic
aorta, and a diagnostic anteroposterior angiogram was
performed, which in all three cases revealed the hyper-
trophic bronchial arteries. The hypertrophic bronchial
arteries were then selectively catheterized with a 5F
cobra-shaped curved catheter. The angiogram showed
minimal to moderate hypervascularity in the right upper
lobe in two cases (Figure 1), whereas in the third case, no
hypervascularity or other obvious vascular abnormality
Figure 1 Selective catheterization of a hypertrophic right bronchial artery in a 56-year-old man with two episodes of severe
hemoptysis. Bronchoscopy detected only some blood trails and clots in the right bronchial system, without conclusive evidence as to the
origin of bleeding. Selective angiography of a hypertrophic right bronchial artery through a 5F cobra catheter demonstrates moderate
hypervascularity, more prominent in the right upper lobe.
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was detected. Transcatheter embolization of the hyper-
trophic bronchial arteries of the right upper lobe was
subsequently performed through the catheter after stabi-
lization of the catheter tip was confirmed (Figure 2).
A microcatheter was not used, as there was no opacifica-
tion of the important spinal branches in any of our three
patients. Tris-acryl gelatin microspheres (Embosphere®;
BioSphere Medical Inc, Marlborough, MA, USA) 500-
700 μm in diameter, were used as the embolization mate-
rial, and were injected slowly through 1 ml syringes. The
embolic particles were dispersed in contrast medium to
allow visualization of any backflow and to monitor for
progressive slowing of flow. Throughout the procedure,
regular angiograms were performed to detect previously
invisible connections to side branches supplying the
spinal cord. Embolization was terminated when the ante-
grade flow ceased.
After the embolization treatment, all three patients
were stable, and none exhibited recurrent hemoptysis.
They expectorated minor amounts of blood-stained spu-
tum, which gradually disappeared within one to three
days. No complications developed in any of the cases as
a result of this intervention. All three patients were dis-
charged three to four days after embolization. Follow up
CT scans at six and 12 months did not show any addi-
tional abnormality except for the aforementioned
emphysema in one of the cases.
Discussion
Life-threatening hemoptysis is one of the most serious
emergencies in pulmonary medicine. The initial approach
is no different than for any other bleeding or hemodyna-
mically unstable patient. According to standard manage-
ment protocols, the physician’s primary goals include
stabilizing the patient and securing the airway, identifying
the bleeding site and efficiently containing the hemor-
rhage [2]. Localization of the bleeding site is usually
accomplished with imaging studies (chest x-ray, CT) and
bronchoscopy. In some cases, however, no underlying
pulmonary pathology can be identified. When no
associated comorbidity can be confidently identified, a
common risk factor is cigarette smoking [10].
Figure 2 Elimination of pathologic hypervascularity after embolization with tris-acryl gelatin microspheres (500-700 μm) injected
through the cobra catheter.
Samara et al. Journal of Medical Case Reports 2011, 5:58
http://www.jmedicalcasereports.com/content/5/1/58
Page 3 of 5
Management of idiopathic hemoptysis is difficult and
challenging [2-4]. Surgery was once regarded as the treat-
ment of choice in operable patients with massive hemop-
tysis. However, inability to localize the bleeding site
makes surgery a poor option. BAE is an excellent non-
surgical alternative. Indications for BAE include failure of
conservative management, massive hemoptysis, recurrent
hemoptysis, and elevated surgical risk. It is also done to
control bleeding temporarily before surgery. According
to a recent report by the Mayo clinic group [5], immedi-
ate control of bleeding is obtained in 94% of patients and
30-day control in 85% of patients. Shigemura et al [11]
reported immediate success in controlling hemoptysis in
88% of cases in a series of 55 patients. Of those, 70% had
no evidence of recurrence after one year of follow-up. It
should be emphasized that after the cessation of bleeding,
it is of great importance to treat any underlying pulmon-
ary process. Another indication for BAE is peripheral
pulmonary artery pseudoaneurysm, which is found in up
to 11% of patients undergoing bronchial angiography for
hemoptysis [12]. Although the efficacy and safety of BAE
has been established in various pathologies causing mas-
sive hemoptysis, there is little information for BAE in
cryptogenic hemoptysis. A recent retrospective study of
cryptogenic hemoptysis in 35 smokers reported cessation
of bleeding by BAE in 29 of 34 technically successful pro-
cedures (85%), and only three of five patients with recur-
rence of bleeding required surgical intervention [10].
Savale et al. [13] reported that first-line conservative
measures and BAE controlled hemoptysis in 73 (90%) of
their patients. Emergency surgery was performed in six
patients (7%) because of failure of BAE, and secondary
surgery was scheduled in a seventh patient.
BAE is described as the emergency treatment of choice
for massive hemoptysis, as the mortality rate ranges from
7.1 to 18.2%, which, although high, is considerably less
than the 40% seen in emergency surgery for massive
hemoptysis [10,11]. Should hemoptysis recur in any trea-
ted patient, a repeat embolization can safely be performed.
If the bleeding recurs one to six months later, the cause is
likely to be incomplete embolization of an undetected
non-bronchial systemic arterial supply. Late recurrences
(6-12 months after the procedure) have been reported in
as many as 2-40% of patients, probably due to disease pro-
gression [12]. Any patient with the diagnosis of crypto-
genic hemoptysis has to be followed up to exclude lung
carcinoma. Multidetector row CT may be helpful in this
regard [13,14]. Emergency surgery for idiopathic hemopty-
sis should only be reserved for cases in which life-threa-
tening bleeding continues to occur despite BAE.
Regarding the optimum embolization material for
BAE, tris-acryl gelatine microspheres seem to be effec-
tive and well tolerated in patients with life-threatening
hemoptysis who are not surgical candidates [15]. As has
been shown in several in vivo and in vitro studies, these
microspheres are characterized by better sizing and
penetration characteristics than the most commonly
used polyvinyl alcohol particles [16,17]. Indeed, to the
best of our knowledge this report is the first to describe
application of tris-acryl gelatine microspheres in conse-
cutive patients with cryptogenic hemoptysis. The larger
size particles (500-700 μm) were selected to avoid pas-
sage of the particles through bronchopulmonary shunts.
We believe that further clinical and experimental studies
are needed to investigate the effectiveness and safety of
BAE with these particles.
BAE has proved to be very effective and lacks the
mortality and morbidity related with surgical alternatives
[4,11,18]. Regarding the complications of BAE, their rate
has diminished gradually over the years, especially when
the technique is performed by skilled and experienced
radiologists. Complications include spinal cord injury,
subintimal dissection of the aorta leading to mediastinal
hematoma, arterial perforation by a guide wire, transient
thoracic pain, shoulder pain and dysphagia [3,5]. The
potential risk of spinal cord injury is the most serious
complication, and must always be considered. Brown-
Sequard syndrome has been reported, as has paraparesis
with spontaneous regression and complete paraplegia
without regression [5]. Finally, shock related to splenic
infarction has been described after a successful BAE
[19]. In the past few years, to prevent a potential neuro-
logic complication developing, ‘superselective’ BAE has
been used, meaning the embolization of more terminal
branches of the arterial tree, beyond the origin of the
spinal arteries. Another complication in patients with
renal failure is contrast nephropathy, the risk of which
must be weighed against the possible consequences,
including death, of not performing BAE in a patient
who cannot undergo surgery [1].
Conclusions
We report the successful treatment by BAE of three
consecutive patients presenting with cryptogenic
hemoptysis. The management of hemoptysis has evolved
during the past decade, favouring a least invasive thera-
peutic approach, as the efficacy and safety of BAE have
been established for controlling hemoptysis (i.e. conser-
vative measures and interventional radiology over emer-
gency surgery). Our findings are in accordance with the
current literature supporting BAE as a safe, non-invasive
tool in the management of idiopathic bronchopulmon-
ary hemoptysis, and advocating the use of embolization
as treatment of choice in such cases. Tris-acryl micro-
spheres appear to be a safe and effective embolization
material for this application.
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